

FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization

Jen-Liang Su^{1,2,3}, Xiaoyun Cheng⁴, Hirohito Yamaguchi⁴, Yi-Wen Chang¹, Chao-Feng Hou¹, Dung-Fang Lee⁴, How-Wen Ko⁴, Kuo-Tai Hua⁷, Ying-Nai Wang^{2,4}, Michael Hsiao⁸, PoShen B. Chen¹, Jung-Mao Hsu⁴, Robert C. Bast Jr⁵, Gabriel N. Hortobagyi⁶, and Mien-Chie Hung^{1,2,3,4}

Abstract

Gene therapy trials in human breast, ovarian, and head and neck tumors indicate that adenovirus E1A can sensitize cancer cells to the cytotoxic effects of paclitaxel *in vitro* and *in vivo*. Resistance to paclitaxel has been reported to occur in cells expressing low levels of the Forkhead transcription factor FOXO3a. In this article, we report that FOXO3a is critical for E1A-mediated chemosensitization to paclitaxel. RNA interference-mediated knockdown of FOXO3a abolished E1A-induced sensitivity to paclitaxel. Mechanistic investigations indicated that E1A indirectly stabilized FOXO3a by acting at an intermediate step to inhibit a ubiquitin-dependent proteolysis pathway involving the E3 ligase β TrCP and the FOXO3a inhibitory kinase IKK β . E1A derepressed this inhibitory pathway by stimulating expression of the protein phosphatase 2A (PP2A)/C protein phosphatases, which by binding to the TGF- β -activated kinase TAK1, inhibited its ability to activate IKK β and, thereby, to suppress β TrCP-mediated degradation of FOXO3a. Thus, by stimulating PP2A/C expression, E1A triggers a signaling cascade that stabilizes FOXO3a and mediates chemosensitization. Our findings provide a leap forward in understanding paclitaxel chemosensitization by E1A, and offer a mechanistic rationale to apply *E1A* gene therapy as an adjuvant for improving therapeutic outcomes in patients receiving paclitaxel treatment. *Cancer Res*; 71(21); 6878–87. ©2011 AACR.

Introduction

Adenovirus type 5 E1A (E1A) was originally recognized as an oncogene that could facilitate oncogenic transformation by other viral and cellular oncogenes. However, E1A has not been associated with human malignancies despite extensive efforts to identify such a link (1). Instead, E1A was shown to have antitumor activities by reversing the transformed phenotype, inhibiting metastasis, and inducing apoptosis in multiple transformed rodent cells and human cancer cell lines (2–6). In addition to the tumor suppressor activities, expression of

the *E1A* gene in stably transfected normal fibroblasts and human cancer cells has been shown to induce sensitization among different categories of anticancer drugs *in vitro*, including etoposide, cisplatin, doxorubicin, gemcitabine, TNF-related apoptosis-inducing ligand (TRAIL), histone deacetylase (HDAC) inhibitors, and paclitaxel in normal fibroblasts and in sarcoma, non-small cell lung, hepatocellular, ovarian, and breast cancer cells (7–12). Furthermore, animal studies showed that the combination of systemic *E1A* gene therapy with paclitaxel significantly enhanced paclitaxel-induced apoptosis and prolonged survival rates in the animal orthotopic model *in vivo* (11, 13). Therefore, *E1A* is, at present, considered a tumor suppressor gene and has been tested in multiple clinical trials in a gene therapy setting for patients with breast (14, 15), ovarian (2, 14), and head and neck cancers (15, 16). A clinical study using *E1A* gene therapy combined with paclitaxel has been initiated for treatment of ovarian cancer. Thus, it is critical and timely to understand the detailed molecular mechanisms that are associated with E1A-mediated chemosensitization, and future clinical trials using the combination of chemotherapy with *E1A* gene therapy can be further improved.

One of the molecular mechanisms by which E1A induces chemosensitization is downregulation of Her-2/neu overexpression (8, 11). Recently, inhibition of Akt and activation of p38 was reported to provide a general cellular mechanism for E1A-mediated chemosensitization (9, 17). Regulation of some critical tumor suppressors was also proposed as being involved in E1A-induced chemosensitization, such as p53 and p19ARF (18), the proapoptotic protein Bax, caspase 9, and a yet-unidentified

Authors' Affiliations: ¹Graduate Institute of Cancer Biology, College of Medicine, China Medical University; ²Center for Molecular Medicine, China Medical University Hospital; ³Department of Biotechnology, Asia University, Taichung, Taiwan; Departments of ⁴Molecular and Cellular Oncology, ⁵Experimental Therapeutics, and ⁶Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; ⁷Institute of Toxicology, College of Medicine, National Taiwan University; and ⁸The Genomics Research Center, Academic Sinica, Taipei, Taiwan

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

Corresponding Authors: Mien-Chie Hung, Department of Molecular and Cellular Oncology, Unit 79, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-3668; Fax: 713-794-3270; E-mail: mhung@mdanderson.org; and Jen-Liang Su, Graduate Institute of Cancer Biology, College of Medicine, China Medical University, No. 6, Hsueh-Shih Road, Taichung 404, Taiwan. Phone: 886-4-22052121, ext. 7932; Fax: 886-4-22333496; E-mail: jlsh@mail.cmu.edu.tw

doi: 10.1158/0008-5472.CAN-11-0295

©2011 American Association for Cancer Research.

inhibitor that ordinarily provides protection against cell death (11, 19–22).

Forkhead box O-class (FOXO) transcription factors include FOXO1 (FKHR; Forkhead in rhabdomyosarcoma), FOXO3a (FKHRL1; FKHR-like 1), and FOXO4 (AFX; acute lymphocytic leukemia-fused gene from chromosome X). The FOXOs activate and/or repress transcription of genes involved in metabolism, apoptosis, DNA damage repair, and cell-cycle progression (23). For example, FOXO3a has been shown to enhance p27^{kip} expression and induce cell-cycle arrest (24). Furthermore, FOXO3a and FOXO4 have been shown to inhibit the cell cycle through downregulation of cyclin D by a p27^{kip}-independent mechanism (25, 26). In breast cancer, FOXO3a has been shown to upregulate Bim, a proapoptotic BH3-only protein (25, 27). The activity of the FOXOs can be inhibited by activating the phosphoinositide 3-kinase (PI3K)/Akt pathway. FOXO3a can be phosphorylated by Akt at 3 conserved serine/threonine residues (Thr-32, Ser-253, and Ser-315), and it subsequently translocates from the nucleus to the cytoplasm, where it is retained by binding to the 14-3-3 protein (28). FOXO3a activity can also be inhibited by the I κ B kinase (IKK) signaling pathway. IKK physically interacts with and phosphorylates FOXO3a independently of Akt, which causes nuclear exclusion of FOXO3a and, subsequently, proteolysis of FOXO3a via the β TrCP-mediated ubiquitin (Ub)-dependent proteasome pathway (29). Recently, extracellular signal-regulated kinase (Erk) was also shown to phosphorylate FOXO3a at Ser-294, Ser-344, and Ser-425 sites, which enhance interaction with the E3 Ub ligase MDM2, resulting in FOXO3a degradation (30). However, the biologic function and detailed molecular mechanism of FOXO3a proteolysis in E1A-mediated chemosensitization are still unclear.

In an attempt to understand the molecular mechanism of E1A-mediated chemosensitization, we found that FOXO3a is critical to that process. E1A stabilizes FOXO3a by preventing β TrCP-mediated Ub-dependent proteolysis through inhibiting the phosphorylation of FOXO3a at Ser-644 by IKK β . E1A induces the expression of protein phosphatase 2A (PP2A; a protein phosphatase involved in multiple cellular functions, including chemosensitization), which inhibits TGF- β -activated kinase 1 (TAK1)-activated IKK signaling, thus stabilizing FOXO3a and inducing chemosensitization.

Materials and Methods

Cell lines, DNA constructs, and antibodies

Cells of the cell lines MDA-MB-231, HeLa, and MDA-157 were purchased from the American Type Culture Collection (ATCC) and grown in Dulbecco's Modified Eagle's Medium (DMEM)/F12 supplemented with 10% FBS. The human breast cancer cell line MDA-MB-231 and its E1A/vector-stable transfectants have been described previously (31). The transfectants were grown under the same conditions as the controls, except that G418 was added to the culture medium. Cell lines have been characterized using DNA analysis by STR fingerprinting (HeLa, March 2009; MDA-MB-231, December 2010; MDA-MB-157, ongoing). Cell lines were frozen after they were received from the ATCC and had not

been passed for more than 6 months in culture when the experiments were carried out.

Plasmids E1A (2), IKK β (29), β TrCP siRNA plasmids (kindly provided by Dr. Serge Y. Fuchs, University of Pennsylvania, Philadelphia, PA), PP2A/A, PP2A/C (17), and TAK1-HA (32) were described previously. FOXO3a siRNA plasmids were kindly provided by Dr. Alex Tokar (Harvard Medical School, Boston, MA).

The monoclonal antibody used against the E1A protein was M58 (Pharmingen). The following were obtained as indicated: HA (11666606001; Roche), FOXO3a (SC-11351; Santa Cruz Biotechnology), IKK β (2684; Cell Signaling Technology, or SC-7607; Santa Cruz Biotechnology), and pIKK β (S181; 2681; Cell Signaling Technology). Rabbit anti-human PP2A/A and PP2A/C antibodies were purchased from CalBiochem. In addition, we purchased the following from the suppliers indicated: Ub (3936; Cell Signaling Technology), β TrCP (37-3400; Zymed, or SC-15354; Santa Cruz Biotechnology), TAK1 (SC-7967; Santa Cruz Biotechnology), pTAK1 (4531S; Cell Signaling Technology), and α -tubulin (T-5168; Sigma). Recombinant human TNF α was purchased from Roche. MG132 was purchased from Sigma.

Immunoprecipitation and Western blotting

Cells were washed twice with PBS, scraped into 500 μ L of lysis buffer, and incubated on ice for 20 minutes. After centrifugation at 14,000 $\times g$ for 10 minutes, 1.5 mg of each supernatant was preincubated with 2 μ g of immunoglobulin G (IgG) and 50 μ L of protein G for 1 hour at 4°C. Immunoprecipitation was carried out overnight with 2 μ g antibody and 50 μ L of protein G. The immunocomplex was washed 5 times with lysis buffer, dissolved in loading buffer, subjected to SDS-PAGE, and transferred onto nitrocellulose membranes. The membranes were blocked with 5% nonfat dry milk in PBS containing 0.05% Tween-20 and incubated with primary antibodies, followed by secondary antibodies (Jackson ImmunoResearch Laboratories). The immunoblots were visualized with enhanced chemiluminescence (Amersham).

Paclitaxel-induced cell death

Cells were treated with 20 nmol/L paclitaxel and incubated for 24 hours. Aliquots of 1×10^6 cells were collected and washed once with ice-cold PBS and then fixed with ice-cold 70% ethanol overnight. After fixation, cells were washed with PBS to remove residual ethanol, pelleted, and resuspended in PBS containing 50 μ g/mL of propidium iodide (PI; Sigma). Staining was done at 4°C for at least 30 minutes, and samples were analyzed using an Epics PROFILE flow cytometer (Coulter) in the Core Facility at The University of Texas MD Anderson Cancer Center (Houston, TX).

Orthotopic breast tumor growth assay

Six-week-old female severe combined immunodeficient (SCID) mice were orthotopically inoculated with tumor cells into the mammary fat pad and treated with vehicle or paclitaxel as described previously (9). Tumor development was followed in individual animals (8 per group) by measuring tumor length (L) and width (W) with calipers every 3 days. Tumor volume was calculated with the formula $LW^2/2$. All




Figure 1. FOXO3a is critical for E1A-mediated chemosensitization. **A**, E1A-expressing vector (E1A) or control vector (vector) was transfected into different types of cells, followed by analysis of E1A, FOXO1, FOXO4, and FOXO3a protein expression using Western blot analysis. α -Tubulin was used as the internal protein loading control. **B**, E1A-induced FOXO3a expression was required for E1A-mediated chemosensitization. Top, chemosensitization of E1A-expressing cells or vector control cells transfected with siFOXO3a or control (Ctrl) siRNA as analyzed by the DNA flow cytometric assay. Each type of transfected cell was treated with 20 nmol/L paclitaxel for 24 hours. The columns are the mean values from 3 independent experiments. Bars indicate means $\pm$ SE. *, statistically significant difference compared with values of column 1 (*, $P < 0.05$, the 2-tailed Student t test). E1A-dependent chemosensitization was overturned by siFOXO3a to a significant degree, as indicated by the # symbol. Bottom, expression of FOXO3a was analyzed by Western blotting. **C**, tumor volume of orthotopic xenograft tumors formed by MDA-MB-231/vector cells or MDA-MB-231/E1A cells stably transfected with either control siRNA

animal work and care were carried out in accordance with protocols approved by the Institutional Animal Care and Use Committee of China Medical University (Taichung, Taiwan).

Results

FOXO3a is critical for E1A-mediated chemosensitization

E1A gene therapy has been shown to induce chemosensitization among different chemotherapeutic agents, including paclitaxel in breast and ovarian cancers (33). It has been shown that resistance to paclitaxel occurs in cells expressing low levels of FOXO3a (34). We, therefore, speculated whether FOXO3a might contribute to E1A-mediated chemosensitization. To this end, we examined the effects of E1A on FOXO3a expression in various types of cancer cells including MDA-MB-231, HeLa, and MDA-MB-157 and found that expression of FOXO3a was significantly increased in E1A-transfected cells (Fig. 1A). We found that FOXO3a-regulated apoptotic genes, such as *FasL* and *p27*, were increased in E1A-transfected cells and decreased by FOXO3a knockdown (Supplementary Fig. S1A) and involved in E1A-mediated chemosensitization (Supplementary Fig. S1B). More importantly, E1A-induced chemosensitization of paclitaxel was abolished by knockdown of FOXO3a expression using FOXO3a-specific small interfering RNA (siFOXO3a) in E1A-transfected MDA-MB-231, HeLa, and MDA-MB-157 cancer cell lines (Fig. 1B). Furthermore, E1A-induced chemosensitization of doxorubicin and cisplatin was reduced by knockdown of FOXO3a (Supplementary Fig. S1C). Using the established stable transfectants, we further investigated the effects of FOXO3a on E1A-mediated chemosensitization in a xenograft tumor model in which mice were injected orthotopically with stably transfected cell clones. The results indicated that E1A induces the chemosensitization of paclitaxel *in vivo*, in that the tumor volume in 231/E1A-bearing mice treated with paclitaxel was significantly less than that in 231/vector-bearing mice treated with paclitaxel ($810.7 \pm 73.2 \text{ mm}^3$ vs. $1,648.7 \pm 237.4 \text{ mm}^3$; Fig. 1C, lane 6 vs. lane 2). E1A-induced chemosensitization to paclitaxel was abolished by knockdown of the expression of FOXO3a by stable expression of siFOXO3a in 231/E1A cells ($810.7 \pm 73.2 \text{ mm}^3$ vs. $1,855.1 \pm 135.8 \text{ mm}^3$; Fig. 1C, lane 6 vs. lane 8). Increased tumor volumes by siFOXO3a treatment in 231/E1A correlated well with reduced FOXO3a expression in the tumors (Fig. 1D). We, therefore, concluded that FOXO3a is required for the E1A-mediated chemosensitization to paclitaxel.

E1A prevents Ub-dependent proteolysis of FOXO3a

Posttranslational modification and regulation of FOXO3a protein stability are critical for FOXO3a activity (29). Therefore, we attempted to determine the stability of FOXO3a protein in response to E1A in breast cancer cells. For this analysis, we treated control vector and E1A-expression vector-stable transfectants (231/vector and 231/E1A) with cycloheximide for

various times to block *de novo* protein synthesis and found that the half-life of FOXO3a protein was more than 7 hours for E1A-transfected cells but less than 1.5 hours for control cells by using Western blot analysis (Fig. 2A). TNF α -mediated FOXO3a polyubiquitination (29) was significantly decreased in 231/E1A cells compared with that in 231/vector cells (Fig. 2B). These results indicate that E1A increases FOXO3a protein expression by preventing Ub-dependent proteolysis of FOXO3a.

β TrCP is involved in E1A-induced FOXO3a induction

β TrCP oncogenic Ub E3-ligase interacts with FOXO3 and induces its Ub-dependent degradation in an IKK β phosphorylation dependent manner (27). Thus, we asked whether β TrCP was involved in E1A-mediated FOXO3a protein stabilization. To this end, we first asked whether β TrCP physically interacted with FOXO3a. We analyzed proteasome inhibitor MG132-treated 231/vector and 231/E1A cell lysates by reciprocal co-immunoprecipitation (IP) followed by immunoblotting (IB) using antibodies against FOXO3a and β TrCP. Our results showed that endogenous FOXO3a was associated with endogenous β TrCP *in vivo* in 231/vector cells and this interaction was stimulated by TNF α treatment. Interestingly, TNF α -induced binding between FOXO3a and β TrCP was significantly reduced in E1A-expressing cells (Fig. 2C). In addition, β TrCP was shown to be required for maintenance of low FOXO3a expression by using siRNA of β TrCP. Transfection with si β TrCP increased FOXO3a expression in 231/vector but not in 231/E1A cells (Fig. 2D). In addition, knockdown of β TrCP abolished the association between FOXO3a and β TrCP (Fig. 2D). Taken together, these results indicate that E1A inhibits interaction of FOXO3a and β TrCP, which may prevent FOXO3a degradation.

Inhibition of TAK1-IKK signaling is required for E1A-mediated prevention of β TrCP/FOXO3a interaction and chemosensitization

It is known that β TrCP interacts with FOXO3 and induces its Ub-dependent degradation in an IKK β -phosphorylation-dependent manner (29). To define whether E1A-mediated FOXO3a stabilization is attributable to prevention of FOXO3a phosphorylation by IKK β and subsequent recognition by β TrCP, we investigated the association between FOXO3a and β TrCP in 231/vector and 231/E1A cells transfected with IKK β -expression plasmid or control vector. Notably, transfection with the IKK β expression vector reestablished the association between FOXO3a and β TrCP in 231/E1A cells (Fig. 3A, left). To further investigate whether inactivation of IKK β by E1A is required for E1A-induced chemosensitization, we transiently transfected E1A expression vector with or without IKK β expression vector into MDA-MB-231 cells and determined the effects of paclitaxel-induced cell death. E1A-induced chemosensitization was strikingly suppressed by transfection with IKK β expression vector (Fig. 3A, right), supporting the notion that E1A-repressed IKK β activity is required for E1A-mediated

(siControl) or FOXO3a siRNA (siFOXO3a). Each column represents the mean $\pm$ SD of 8 primary tumors. *, $P < 0.05$ versus column 2 values, by the 2-tailed Student *t* test. E1A-dependent chemosensitization was overturned by siFOXO3a to a significant degree, as indicated by the # symbol. D, expression of FOXO3a protein and E1A was examined by immunoblotting assays using MDA-MB-231/vector tumors or MDA-MB-231/E1A tumors stably transfected with either control siRNA (siControl) or FOXO3a siRNA (siFOXO3a) in combination with paclitaxel treatment.




Figure 2. E1A prevents β TrCP-mediated ubiquitin-dependent proteolysis of FOXO3a. **A**, determination of the protein stability of FOXO3a in MDA-MB-231/vector cells and MDA-MB-231/E1A cells. The 231/vector cells and 231/E1A cells were treated with 100 μ g/mL cycloheximide (CHX) for the indicated times. Total protein was isolated, and expression of FOXO3a was analyzed by Western blot assay and quantified (bottom). The results are representative of at least 3 independent experiments. Error bars, SD. **B**, top, 231/vector or 231/E1A cells transfected with HA-ubiquitin (HA-Ub) were treated with the proteasome inhibitor MG132 with or without TNF α (50 ng/mL), and the lysates of these cells were analyzed using immunoprecipitation (IP)/immunoblotting (IB). Bottom, lysates of 231/vector or 231/E1A cells transfected with HA-Ub were subjected to Western blotting. **C**, 231/vector or 231/E1A cells were treated with the proteasome inhibitor MG132 with or without TNF α (50 ng/mL), and the lysates of these cells were analyzed by IP/IB. **D**, knockdown of β TrCP expression by β TrCP-specific siRNAs increased FOXO3a expression and disrupted the interaction between β TrCP and FOXO3a. The 231/vector cells and 231/E1A cells were transfected with si β TrCP or control siRNA. Forty-eight hours after transfection, total proteins were isolated, and expression of FOXO3a and β TrCP was analyzed by Western blotting. Lysates of 231/vector or 231/E1A cells transfected with si β TrCP or control siRNA in the presence of MG132 (5 μ mol/L) were analyzed by IP/IB (anti-FOXO3a/anti- β TrCP).

paclitaxel chemosensitization. To determine whether the Ser-644-phosphorylated FOXO3a is capable of reestablishing the association between FOXO3a and β TrCP in 231/E1A cells, we transfected the GFP-tagged Ser-644 phosphorylation-mimic mutant FOXO3a, GFP-FOXO3a-S644E, into 231/vector and 231/E1A cells. Expression of GFP-FOXO3a-S644E reestablished the association between FOXO3a and β TrCP in 231/E1A cells (Supplementary Fig. S2). The above-described data indicated that phosphorylation of FOXO3a at Ser-644 is critical for the association between FOXO3a and β TrCP. To further define whether Akt and ERK signaling pathways are involved in E1A-mediated FOXO3a expression and paclitaxel chemosensitization, we modulated these 2 kinases by a specific inhibitor or genetic modulation. On one hand, E1A-induced FOXO3a expression and chemosensitization were suppressed by transfection with constitutively activated Akt (Myr-Akt) expression

vector (Supplementary Fig. S3). On the other hand, we found that treatment with a MAP/ERK kinase (MEK) inhibitor, U0126, slightly increased FOXO3a expression and paclitaxel chemosensitization in 231/vector cells but not in 231/E1A cells (Supplementary Fig. S4). The above-described data indicate that the Akt but not ERK signaling pathway may also be involved in E1A-mediated FOXO3a regulation and paclitaxel chemosensitization.

To explore the mechanism(s) through which inhibition of IKK activity participates in the cellular responses to E1A, we determined the phosphorylation of IKK in 231/vector and 231/E1A cells. Consistent with a previous report (35), treatment with TNF α increased the phosphorylation of IKK in 231/vector cells, but this activation was abolished in 231/E1A cells (Fig. 3B). These data indicated that E1A-induced inhibition of IKK signaling may target the upstream kinase of IKK. Recent




Figure 3. Inhibition of TAK1-IKK β signaling is required for E1A-mediated prevention of β TrCP/FOXO3a interaction and chemosensitization. **A**, IKK β was required for E1A-mediated prevention of interaction between β TrCP and FOXO3a and chemosensitization. Left, lysates of 231/vector cells and 231/E1A cells transfected with the HA-IKK β expression vector in the presence of MG132 (5 μ M) were analyzed by IP/IB (anti-FOXO3a/anti- β TrCP, anti-FOXO3a). Right, chemosensitization of 231/E1A and 231/vector cells transfected with HA-IKK β expression plasmid or control vector as analyzed by the DNA flow cytometric assay. Each type of transfected cell was treated with 20 nmol/L paclitaxel for 24 hours. The columns are the mean values from the 3 independent experiments. Bars indicated means $\pm$ SE. *, statistically significant difference compared with values of group 1 (*, $P < 0.05$, the 2-tailed Student t test). E1A-dependent chemosensitization was overturned by HA-IKK β to a significant degree, as indicated by the # symbol. **B**, lysates of MDA-MB-231/vector and MDA-MB-231/E1A cells left untreated or treated with TNF α (50 ng/mL) were subjected to Western blotting to analyze the phosphorylation of IKK and TAK1. **C**, lysates of 231/vector and 231/E1A cells transfected with or without HA-TAK1 expression plasmid were subjected to Western blotting to analyze the expression of FOXO3a and phosphorylated IKK protein (left). The interaction between β TrCP and FOXO3a was determined by IP and Western blotting (right). **D**, 231/E1A and 231/vector cells were transfected with HA-TAK1 expression plasmid or control vector and then analyzed for paclitaxel-induced cell death by DNA flow cytometry. Each type of transfected cells was treated with 20 nmol/L paclitaxel for 24 hours. The columns are the mean values from the 3 independent experiments. Bars indicate means $\pm$ SE. *, statistically significant difference compared with values of column 1 (*, $P < 0.05$, the 2-tailed Student t test). E1A-dependent chemosensitization was overturned to a significant degree by overexpression of HA-TAK1, as indicated by the # symbol.

evidence indicates that TAK1 is essential for the activation of IKK in multiple signaling pathways (26). Therefore, we investigated the possible involvement of TAK1 in E1A-mediated inhibition of IKK signaling, FOXO3a stabilization, and chemosensitization. We found that treatment with TNF α increased the phosphorylation of TAK1 in 231/vector cells, and this TNF α -induced phosphorylation was diminished by expression of E1A (Fig. 3B). Furthermore, transfection with the HA-TAK1 expression vector significantly increased phosphorylation of IKK, and the E1A-mediated downregulation of p-IKK was overcome by the forced expression of HA-TAK1 (Fig. 3C, left). Experiments were also carried out to ascertain whether TAK1 is involved in E1A-mediated FOXO3a interaction with β TrCP and chemosensitization. Forced expression of HA-TAK1 significantly increased the interaction between FOXO3a and β TrCP in 231/vector cells, and the E1A-mediated inhibition effect was also recovered by exogenous expression of HA-TAK1

(Fig. 3C, right). Consistently, E1A-mediated chemosensitization to paclitaxel was significantly impaired by expression of TAK1 (Fig. 3D). Taken together, these data indicate that TAK1, the upstream kinase of IKK, is a critical regulator for E1A-repressed FOXO3a interaction with β TrCP and is required for E1A-mediated chemosensitization.

E1A-induced PP2A expression is required for regulation of TAK1-IKK signaling, β TrCP/FOXO3a interaction, and chemosensitization

Phosphorylation of protein kinases is tightly regulated by related protein phosphatases, and it has been reported that E1A increases the expression of PP2A/C, the catalytic subunit of PP2A (14). Because E1A inhibits TAK1 phosphorylation, we asked whether PP2A might be involved in E1A-mediated dephosphorylation of TAK1 and IKK and FOXO3a stabilization. To this end, 231/vector and 231/E1A cells were




Figure 4. E1A-induced PP2A expression is required for regulation of TAK1-IKK signaling, β TrCP/FOXO3a interaction, and chemosensitization. **A**, Western blot analyses of the phosphorylation of TAK1 and IKK and the interaction between FOXO3a and β TrCP in MDA-MB-231/vector and MDA-MB-231/E1A cells left untreated or treated with TNF α (50 ng/mL) and 10 nmol/L OA. Equal amounts of cell lysates were subjected to Western blotting with specific antiphosphorylated TAK1 and IKK antibodies and anti-TAK1 and IKK antibodies. The results are representative of at least 3 independent experiments. The cell lysates were also subjected to IP/IB (anti-FOXO3a/anti- β TrCP) analysis. **B**, 231/E1A and 231/vector cells were untreated or treated with OA (10 nmol/L) combined with 20 nmol/L paclitaxel for 24 hours and then analyzed for chemosensitization by DNA flow cytometry. The columns are the means of 3 independent experiments. Bars indicate means $\pm$ SE. *, statistically significant difference compared with values of column 1 (*, $P < 0.05$, the 2-tailed Student t test). E1A-dependent chemosensitization was overturned to a significant degree by treatment with OA, as indicated by the # symbol. **C**, E1A-induced PP2A/C expression was required for E1A-mediated signaling. Lysates of 231/vector and 231/E1A cells transfected with siPP2A/C or control siRNA were subjected to IP/IB (anti-TAK1/anti-IKK and anti-PP2A/C) analysis and Western blotting (PP2A/C and PP2A/A). **D**, lysates of 231/vector and 231/E1A cells transfected with siPP2A/C or control siRNA were subjected to IP/IB (anti-FOXO3a/anti-FOXO3a and anti- β TrCP) analysis.


treated with the phosphatase inhibitor okadaic acid (OA). We found that E1A-mediated inhibition of TNF α -induced TAK1 phosphorylation was restored by OA treatment, as were E1A-mediated inhibition of IKK phosphorylation and the interaction between FOXO3a and β TrCP (Fig. 4A). Consistently, E1A-induced chemosensitization was also decreased in 231/E1A cells by treatment with OA (Fig. 4B). We next examined whether PP2A binds to TAK1. As shown in Fig. 4C, treatment with TNF α notably increased the interaction between TAK1 and IKK in 231/vector cells but not in 231/E1A cells. Moreover, PP2A/C formed a complex with TAK1 in 231/E1A cells and severely impaired the TNF α -induced interaction between TAK1 and IKK (Fig. 4C).

To confirm this novel binding between PP2A and TAK1, we transfected 231/vector and 231/E1A cells with siRNA for catalytic subunit of PP2A, PP2A/C, (siPP2A/C) to target knock-

down of PP2A/C protein and then measured the binding preference of TAK1. Transfection with siPP2A/C, but not with control siRNA, decreased E1A-induced PP2A/C expression (Fig. 4C), and accordingly affected the binding complex of TAK1 and PP2A/C in 231/E1A cells. Interestingly, the formation of TAK1/IKK β complex was significantly increased by siPP2A/C (Fig. 4C, lane 7). E1A-mediated inhibition of the interaction between FOXO3a and β TrCP was also restored by knockdown of siPP2A/C (Fig. 4D, lane 7). These findings indicate that E1A-induced PP2A/C expression is required for regulation of TAK1/IKK signaling, β TrCP/FOXO3a interaction, and chemosensitization.

In summary, we found that FOXO3a is critical for E1A-mediated chemosensitization. E1A stabilizes FOXO3a by inducing the expression of PP2A/C and results in enhanced PP2A phosphatase activity. The enhanced PP2A/C interacts

Figure 5. A model of molecular mechanisms involved in E1A-mediated chemosensitization. In this model E1A stabilizes FOXO3a by inducing the expression of PP2A/C, which inhibits the activation of IKK β through binding and inactivation of TAK1, thus inhibiting IKK β -mediated FOXO3a phosphorylation at Ser-644 and preventing β TrCP-induced FOXO3a degradation and, thereby, inducing chemosensitization.



and dephosphorylates TAK1 to inactivate TAK1, which also renders inactivation of IKK β , thus inhibiting IKK β -mediated interaction between β TrCP and FOXO3a and preventing β TrCP-induced FOXO3a degradation (Fig. 5).

Discussion

E1A is associated with many antitumor activities and has been tested in multiple clinical trials. Studies have shown that, although E1A gene therapy is safe and well tolerated, the tumor response to it is only modest (14–16). However, E1A has been shown to induce sensitization to apoptosis induced by different categories of anticancer drugs; therefore, one improvement that might render E1A more useful as an anticancer therapy is the combination of E1A gene therapy with conventional chemotherapy. Paclitaxel is a front-line chemotherapeutic agent for the treatment of human breast and ovarian cancer. One of the mechanisms that paclitaxel uses to induce apoptosis in cancer cells is through increasing Bim (proapoptotic BH3-only protein) expression by activated FOXO3a activity (34). In the present study, we found that E1A can stabilize FOXO3a, thus

sensitizing MDA-MB-231 breast cancer cells to paclitaxel-induced apoptosis both *in vitro* and *in vivo*. This result provides a molecular mechanism for stronger antitumor strategy by combination of E1A gene therapy and paclitaxel chemotherapy (11, 13, 33). It should be mentioned that the identified molecular mechanism for E1A-induced FOXO3a expression was not observed in the MDA-MB-468 cell line, indicating that this mechanism might be cell-type specific.

We found that E1A can protect FOXO3a from degradation by inhibiting its ubiquitination, although previous studies showed that FOXO3a can be targeted by the proteasome pathway after being phosphorylated by Akt or IKK (28, 29). It is worth mentioning that FOXO3a was also shown to be phosphorylated by Erk at different sites and the phospho-FOXO3a by Erk can be degraded by an E3-Ub ligase MDM2 (30). Our data indicate that the ERK signaling pathway may not be involved in E1A-mediated FOXO3a regulation and paclitaxel chemosensitization. Although the mechanism is not yet clear, a possible reason that the ERK signaling may not be involved could be that ERK-mediated degradation of FOXO3a, unlike Akt and IKK, occurs through MDM2 (30), and E1A can regulate members of the

MDM2 family. For instance, it is known that E1A can bind to MDM4 to inhibit MDM2-induced degradation of p53 (36). Recently, a study has indicated that β TrCP1 oncogenic E3-Ub ligase interacts with FOXO3 and induces its Ub-dependent degradation in an IKK β phosphorylation-dependent manner (37). In our study, we found that β TrCP can physically bind to FOXO3a and mediate its degradation and that E1A stabilizes FOXO3a by inhibiting the binding of FOXO3a to β TrCP. β TrCP is the substrate-recognition subunit of the Skp1 Cullin1 F-box protein E3-Ub protein ligase that can recognize specifically phosphorylated substrates and confer their ubiquitination. β TrCP plays a key role in the NF- κ B signaling pathway by recognizing IKK-phosphorylated I κ B and mediating its degradation (38). Our findings revealed a new substrate of β TrCP that requires phosphorylation by IKK. Previous studies showed that IKK can phosphorylate FOXO3a at Ser-644 and cause FOXO3a nuclear exclusion (29). Consistent with the report by Tsai and colleagues (37), we found that Ser-644 phosphorylation mediated by IKK is also required for FOXO3a binding to β TrCP and for further degradation induced through β TrCP. E1A prevents the binding of β TrCP to FOXO3a by inhibiting the IKK-mediated FOXO3a phosphorylation at Ser-644.

IKK activation requires its phosphorylation by upstream kinases, including TAK1 (39), and phosphorylation plays a significant role in TAK1 activation (40). We found, in this study, that E1A inhibits FOXO3a binding to β TrCP by preventing TAK1 activation and its effect on IKK activation. It was previously shown that TRAF6 and RIP1 can activate TAK1 and lead to IKK phosphorylation and activation (41, 42). However, overexpression of TRAF6 or RIP1 in E1A-stable cell lines did not restore TAK1 activation and mediate FOXO3a degradation (data not shown), indicating that prevention of TAK1 activation by E1A is not mediated by these 2 upstream activators. It is known that PP2A phosphatase activity is enhanced in E1A-expressing cells through E1A-mediated upregulation of PP2A/C expression, which results in repression of Akt activation (17). A previous study indicates that PP2A functions as a negative regulator in TGF- β 1-induced TAK1 activation (43). Therefore, E1A-mediated upregulation of PP2A/C is involved in TAK1 inactivation and inhibits the binding of TAK1 to IKK, which abolishes the function of IKK in phosphorylating FOXO3a, resulting in the stabilization of FOXO3a.

The activities of protein kinases are finely regulated by phosphorylation and dephosphorylation; however, little is known about the dephosphorylation and respective protein phosphatase involved in the regulation of TAK1. PP2A is a ubiquitously expressed protein serine/threonine phosphatase that accounts for the tumor suppression activity in eukaryotic cells. Mutation of PP2A was found in human breast, colon, and lung cancers, and in melanoma (44). In addition, a variety of mechanisms for inactivating PP2A were found to be involved in transformed cells. PP2A can be inhibited by the small T antigen of the DNA tumor virus SV40 (45), by upregulation of the *c-Myc*-specific inhibitor CIP2A (46), or through the upregulation of SET protein by the *BCR/ABL* oncogene (47). It was previously shown that PP2A can suppress Akt (17) and RalA (48) activation, thus inhibiting both PI3K/Akt and ERK signaling pathways (49). We found, in this study, that TAK1 is a target of PP2A/C in another important signaling pathway—the IKK pathway (50). Therefore, PP2A may inhibit the 3 major oncogenic kinase pathways, PI3K/Akt, ERK, and IKK, to exert its tumor suppressor activity. E1A, through upregulation of PP2A/C to stimulate PP2A phosphatase activity, may share these same pathways to suppress tumor development.

tase that accounts for the tumor suppression activity in eukaryotic cells. Mutation of PP2A was found in human breast, colon, and lung cancers, and in melanoma (44). In addition, a variety of mechanisms for inactivating PP2A were found to be involved in transformed cells. PP2A can be inhibited by the small T antigen of the DNA tumor virus SV40 (45), by upregulation of the *c-Myc*-specific inhibitor CIP2A (46), or through the upregulation of SET protein by the *BCR/ABL* oncogene (47). It was previously shown that PP2A can suppress Akt (17) and RalA (48) activation, thus inhibiting both PI3K/Akt and ERK signaling pathways (49). We found, in this study, that TAK1 is a target of PP2A/C in another important signaling pathway—the IKK pathway (50). Therefore, PP2A may inhibit the 3 major oncogenic kinase pathways, PI3K/Akt, ERK, and IKK, to exert its tumor suppressor activity. E1A, through upregulation of PP2A/C to stimulate PP2A phosphatase activity, may share these same pathways to suppress tumor development.

Disclosure of Potential Conflict of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank Drs. X. Lin, M. Karin, A. Tokar, and S.Y. Fuchs for providing reagents and Dr. E.W. McIntush from the Bethyl Laboratory for generating antibodies.

Grant Support

This work was partially supported by NIH grants R01 CA109311 and P01 CA099031 and grants by the Kadoorie Charitable Foundations and the National Breast Cancer Foundation, Inc., M.-C. Hung; by NIH SPOR grants in Ovarian Cancer CA83639 (R.C. Bast Jr. and M.-C. Hung) and Breast Cancer CA116199 (G. Hortobagyi and M.-C. Hung); the University of Texas MD Anderson/China Medical University and Hospital Sister Institution Fund, DOH-TD-C-111-005, by Cancer Center Support Grant CA16672, and a Breast Cancer Research Foundation grant to M.-C. Hung; by NSC-2632-B-001-MY3 (M.-C. Hung and J.-L. Su) and National Science Council grants NSC 96-2320-B-004-MY2, NSC 97-2320-B-039-039-MY3, NSC 98-2815-C-039-082-B; by National Health Research Institutes grants from Taiwan (NHRI-EX98-9712BC, NHRI-EX99-9712BC, NHRI-EX100-9712BC); by the Department of Health, Executive Yuan grant from Taiwan (DOH99-TD-G111-011); by grants from China Medical University (CMU96-220, CMU97-077, CMU99-TC-22 and CMU97-277); and an Odyssey Scholarship from MD Anderson Cancer Center to J.-L. Su. This study was supported in part by the Taiwan Department of Health Clinical Trial and Research Center of Excellence (grant no. DOH100-TD-B-111-004).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 25, 2011; revised August 17, 2011; accepted August 29, 2011; published OnlineFirst September 12, 2011.

References

1. Yu D, Hung MC. The *erbB2* gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A. *Cancer Metastasis Rev* 1998;17:195–202.
2. Ueno NT, Yu D, Hung MC. E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy. *Breast Cancer* 2001;8:285–93.
3. Yu D, Hamada J, Zhang H, Nicolson GL, Hung MC. Mechanisms of *c-erbB2/neu* oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. *Oncogene* 1992;7:2263–70.
4. Deng J, Xia W, Hung MC. Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis *in vivo*. *Oncogene* 1998;17:2167–75.
5. Hung MC, Hortobagyi GN, Ueno NT. Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer. *Adv Exp Med Biol* 2000;465:171–80.
6. Frisch SM, Mymryk JS. Adenovirus-5 E1A: paradox and paradigm. *Nat Rev Mol Cell Biol* 2002;3:441–52.
7. Frisch SM, Dolter KE. Adenovirus E1a-mediated tumor suppression by a *c-erbB-2/neu*-independent mechanism. *Cancer Res* 1995;55:5551–5.

8. Brader KR, Wolf JK, Hung MC, Yu D, Crispens MA, van Golen KL, et al. Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism. *Clin Cancer Res* 1997;3:2017–24.
9. Liao Y, Hung MC. Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis. *Mol Cell Biol* 2003;23:6836–48.
10. Lee WP, Tai DI, Tsai SL, Yeh CT, Chao Y, Lee SD, et al. Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine. *Cancer Res* 2003;63:6229–36.
11. Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, et al. E1A-mediated paclitaxel sensitization in HER-2/neu-over-expressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. *Clin Cancer Res* 2000;6:250–9.
12. Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neu-over-expressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. *Oncogene* 1997;15:953–60.
13. Liao Y, Zou YY, Xia WY, Hung MC. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer. *Cancer Gene Ther* 2004;11:594–602.
14. Hortobagyi GN, Hung MC, Lopez-Berestein G. A phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer. *Hum Gene Ther* 1998;9:1775–98.
15. Yoo GH, Hung MC, Lopez-Berestein G, LaFollette S, Ensley JF, Carey M, et al. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. *Clin Cancer Res* 2001;7:1237–45.
16. Villaret D, Glisson B, Kenady D, Hanna E, Carey M, Gleich L, et al. A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. *Head Neck* 2002;24:661–9.
17. Liao Y, Hung MC. A new role of protein phosphatase 2a in adenoviral E1A protein-mediated sensitization to anticancer drug-induced apoptosis in human breast cancer cells. *Cancer Res* 2004;64:5938–42.
18. deStanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, et al. E1A signaling to p53 involves the p19(ARF) tumor suppressor. *Genes Dev* 1998;12:2434–42.
19. Duelli DM, Lazebnik YA. Primary cells suppress oncogene-dependent apoptosis. *Nat Cell Biol* 2000;2:859–62.
20. McCurrach ME, Connor TM, Knudson CM, Korsmeyer SJ, Lowe SW. Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. *Proc Natl Acad Sci U S A* 1997;94:2345–9.
21. Putzer BM, Stiewe T, Parssanedjad K, Rega S, Esche H. E1A is sufficient by itself to induce apoptosis independent of p53 and other adenoviral gene products. *Cell Death Differ* 2000;7:177–88.
22. Teodoro JG, Shore GC, Branton PE. Adenovirus E1A proteins induce apoptosis by both p53-dependent and p53-independent mechanisms. *Oncogene* 1995;11:467–74.
23. Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. *Cell* 2004;117:421–6.
24. Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. *Nature* 2000;404:782–7.
25. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffey PJ. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. *Curr Biol* 2000;10:1201–4.
26. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaier R, Kops GJ, Lam EW, et al. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. *Mol Cell Biol* 2002;22:7842–52.
27. Gilley J, Coffey PJ, Ham J. FOXO transcription factors directly activate *bim* gene expression and promote apoptosis in sympathetic neurons. *J Cell Biol* 2003;162:613–22.
28. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylation and inhibiting a Forkhead transcription factor. *Cell* 1999;96:857–68.
29. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. *Cell* 2004;117:225–37.
30. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. *Nat Cell Biol* 2008;10:138–48.
31. Yu D, Wolf JK, Scanlon M, Price JE, Hung MC. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. *Cancer Res* 1993;53:891–8.
32. Blonska M, Shambharkar PB, Kobayashi M, Zhang D, Sakurai H, Su B, et al. TAK1 is recruited to the tumor necrosis factor-alpha (TNF-alpha) receptor 1 complex in a receptor-interacting protein (RIP)-dependent manner and cooperates with MEKK3 leading to NF-kappaB activation. *J Biol Chem* 2005;280:43056–63.
33. Liao Y, Yu D, Hung MC. Novel approaches for chemosensitization of breast cancer cells: the E1A story. *Adv Exp Med Biol* 2007;608:144–69.
34. Susters A, Fernandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA, et al. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. *J Biol Chem* 2003;278:49795–805.
35. Shao R, Hu MC, Zhou BP, Lin SY, Chiao PJ, von Lindern RH, et al. E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IkappaB kinases and nuclear factor kappaB activities. *J Biol Chem* 1999;274:21495–8.
36. Li Z, Day CP, Yang JY, Tsai WB, Lozano G, Shih HM, et al. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. *Cancer Res* 2004;64:9080–5.
37. Tsai WBCY, Zou Y, Park SH, Xu Z, Nakayama K, Lin SH, Hu MC. Inhibition of FOXO3 tumor suppressor function by beta-TrCP1 through ubiquitin-mediated degradation in a tumor mouse model. *PLoS One* 2010;5:e11171.
38. Fuchs SY, Spiegelman VS, Kumar KG. The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. *Oncogene* 2004;23:2028–36.
39. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. *Nature* 2001;412:346–51.
40. Singhirunusorn P, Suzuki S, Kawasaki N, Saiki I, Sakurai H. Critical roles of threonine 187 phosphorylation in cellular stress-induced rapid and transient activation of transforming growth factor-beta-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2. *J Biol Chem* 2005;280:7359–68.
41. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. *Nature* 1999;398:252–6.
42. Ting AT, Pimentel-Muinos FX, Seed B. RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. *EMBO J* 1996;15:6189–96.
43. Kim SI, Kwak JH, Wang L, Choi ME. Protein phosphatase 2A is a negative regulator of transforming growth factor-beta-induced activation in mesangial cells. *J Biol Chem* 2008;283:10753–63.
44. Schonthal AH. Role of serine/threonine protein phosphatase 2A in cancer. *Cancer Lett* 2001;170:1–13.
45. Arroyo JD, Hahn WC. Involvement of PP2A in viral and cellular transformation. *Oncogene* 2005;24:7746–55.
46. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, et al. CIP2A inhibits PP2A in human malignancies. *Cell* 2007;130:51–62.
47. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. *Cancer Cell* 2005;8:355–68.
48. Sablina AA, Chen W, Arroyo JD, Corral L, Hector M, Bulmer SE, et al. The tumor suppressor PP2A Abeta regulates the RalA GTPase. *Cell* 2007;129:969–82.
49. Mumby M. PP2A: unveiling a reluctant tumor suppressor. *Cell* 2007;130:21–4.
50. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. *Cell* 2007;130:440–55.